Value in Health

Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical Trials
pp. 281-291(11)
Authors: Torti, Frank M.; Reed, Shelby D.; Schulman, Kevin A.

Implantable or External Defibrillators for Individuals at Increased Risk of Cardiac Arrest: Where Cost-Effectiveness Hits Fiscal Reality
pp. 292-302(11)
Authors: Cram, Peter; Katz, David; Vijan, Sandeep; Kent, David M.; Langa, Kenneth M.; Fendrick, A. Mark

Eliciting Stated Preferences for Health-Technology Adoption Criteria Using Paired Comparisons and Recommendation Judgments
pp. 303-311(9)
Authors: Johnson, F. Reed; Backhouse, Martin

Development of a Smiling Touchscreen Multimedia Program for HRQoL Assessment in Subjects with Varying Levels of Literacy
pp. 312-319(8)
Authors: Thumboo, Julian; Wee, Hwee-Lin; Cheung, Yin-Bun; Machin, David; Luo, Nan; Fong, Kok-Yong

Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version
pp. 320-333(14)
Authors: Woodcock, Alison; Bradley, Clare

Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials
pp. 334-340(7)
Authors: Doshi, Jalpa A.; Glick, Henry A.; Polsky, Daniel

A Dollar Is a Dollar Is a Dollar—or Is It?
pp. 341-347(7)
Authors: Brouwer, Werner B. F.; van Exel, N. Job A.; Baltussen, Rob M. P. M.; Rutten, Frans F. H.

Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States
pp. 348-356(9)
Authors: Coyne, Karin S.; Paramore, Clark; Grandy, Susan; Mercader, Marco; Reynolds, Matthew; Zimetbaum, Peter

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Comment
pp. 357-357(1)

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment
pp. 358-358(1)

Erratum
pp. 359-359(1)